Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab.
Marrocco I, Giri S, Simoni-Nieves A, Gupta N, Rudnitsky A, Haga Y, Romaniello D, Sekar A, Zerbib M, Oren R, Lindzen M, Fard D, Tsutsumi Y, Lauriola M, Tamagnone L, Yarden Y. Marrocco I, et al. Among authors: oren r. Cell Rep Med. 2023 Aug 15;4(8):101142. doi: 10.1016/j.xcrm.2023.101142. Epub 2023 Aug 8. Cell Rep Med. 2023. PMID: 37557179 Free PMC article.
Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor.
Romaniello D, Marrocco I, Belugali Nataraj N, Ferrer I, Drago-Garcia D, Vaknin I, Oren R, Lindzen M, Ghosh S, Kreitman M, Kittel JC, Gaborit N, Bergado Baez G, Sanchez B, Eilam R, Pikarsky E, Paz-Ares L, Yarden Y. Romaniello D, et al. Among authors: oren r. Cancers (Basel). 2020 Aug 24;12(9):2394. doi: 10.3390/cancers12092394. Cancers (Basel). 2020. PMID: 32847130 Free PMC article.
A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.
Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai BR, Van Daele M, Love D, Haga Y, Romaniello D, Salame TM, Zerbib M, Oren R, Tsutsumi Y, Lauriola M, Marrocco I, Yarden Y. Simoni-Nieves A, et al. Among authors: oren r. Cell Rep Med. 2024 Sep 17;5(9):101703. doi: 10.1016/j.xcrm.2024.101703. Epub 2024 Aug 30. Cell Rep Med. 2024. PMID: 39216477 Free PMC article.
Temporal genomic analysis of homogeneous tumor models reveals key regulators of immune evasion in melanoma.
Cohen Shvefel S, Pai JA, Cao Y, Pal LR, Bartok O, Levy R, Zemanek MJ, Weller C, Herzog E, Yao W, Hiam-Galvez KJ, Cheng K, Yin Y, Du PP, Raposo CJ, Gumpert N, Welti M, Martínez Gómez JM, Sella F, Yakubovich E, Orr I, Ben-Dor S, Oren R, Fellus-Alyagor L, Golani O, Brenner OJ, Salame TM, Zerbib M, Goliand I, Ranmar D, Savchenko I, Ketrarou N, Schaffer AA, Dahan R, Levesque MP, Ruppin E, Satpathy AT, Samuels Y. Cohen Shvefel S, et al. Among authors: oren r. Cancer Discov. 2024 Nov 20. doi: 10.1158/2159-8290.CD-23-1422. Online ahead of print. Cancer Discov. 2024. PMID: 39715301
Whole Organ Blood and Lymphatic Vessels Imaging (WOBLI).
Oren R, Fellus-Alyagor L, Addadi Y, Bochner F, Gutman H, Blumenreich S, Dafni H, Dekel N, Neeman M, Lazar S. Oren R, et al. Sci Rep. 2018 Jan 23;8(1):1412. doi: 10.1038/s41598-018-19663-w. Sci Rep. 2018. PMID: 29362484 Free PMC article.
393 results